Financials in USD. Standardized financial statements.
A compact view of how BioXcel Therapeutics, Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $642,000 | $2.27M | $1.38M | $375,000 | $0 | $0 | $0 | $0 | $0 | $0 |
| Revenue Growth? | -71.7% | +64.2% | +268.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Cost of Revenue? | $164,000 | $2.14M | $1.26M | $20,000 | $0 | $0 | $156,000 | $17,000 | $1,000 | $0 |
| Gross Profit? | $478,000 | $123,000 | $120,000 | $355,000 | $0 | $0 | -$156,000 | -$17,000 | -$1,000 | $0 |
| Gross Margin? | +74.5% | +5.4% | +8.7% | +94.7% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating Expenses? | $50.74M | $67.37M | $171.90M | $160.00M | $106.94M | $82.30M | $33.60M | $19.96M | $4.54M | $2.12M |
| Operating Income? | -$50.27M | -$67.25M | -$171.78M | -$159.65M | -$106.94M | -$82.30M | -$33.60M | -$19.96M | -$4.54M | -$2.12M |
| EBITDA? | -$52.61M | -$44.16M | -$165.42M | -$157.22M | -$106.59M | -$82.11M | -$32.81M | -$19.25M | -$4.54M | $0 |
| Income Before Tax | -$69.90M | -$59.60M | -$179.05M | -$165.76M | -$106.93M | -$82.17M | -$32.97M | -$19.27M | -$4.54M | -$2.12M |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income? | -$69.90M | -$59.60M | -$179.05M | -$165.76M | -$106.93M | -$82.17M | -$32.34M | -$19.27M | -$4.54M | -$2.12M |
| EPS? | $-5.73 | $-23.51 | $-98.35 | $-94.67 | $-64.87 | $-60.63 | $-32.38 | $-21.16 | $-4.41 | $-2.06 |
| Diluted EPS? | $-5.73 | $-23.51 | $-98.35 | $-94.67 | $-64.87 | $-60.63 | $-32.38 | $-21.16 | $-4.41 | $-2.06 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality